The Effects of Coenzyme Q10 Supplementation on Glucose Metabolism, Lipid Profiles, Inflammation, and Oxidative Stress in Patients With Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial (Publication with Expression of Concern)

Objective: Data on the effects of coenzyme Q10 (CoQ10) supplementation on glucose metabolism, lipid profiles, inflammation, and oxidative stress in subjects with diabetic nephropathy (DN) are scarce. This research was done to determine the effects of CoQ10 supplementation on metabolic status in subjects with DN.Methods: This randomized double-blind placebo-controlled clinical trial was done in 50 subjects with DN. Participants were randomly assigned into two groups to intake either 100mg/day CoQ10 supplements (n = 25) or placebo (n = 25) for 12weeks. Fasting blood samples were obtained at first and after 12-week intervention to quantify metabolic profiles.Results: After 12weeks of treatment, compared with the placebo, CoQ10 supplementation resulted in significant decreases in serum insulin levels (-3.4 6.8vs +0.8 +/- 6.4 mu IU/mL, p = 0.02), homeostasis model of assessment-estimated insulin resistance (-1.0 +/- 2.0vs +0.2 +/- 1.8, p = 0.03), homeostasis model of assessment-estimated B cell function (-12.3 +/- 26.3vs +3.5 +/- 23.1, p = 0.02) and HbA1c (-1.1 +/- 1.0vs -0.1 +/- 0.2%, p < 0.001), and a significant improvement in quantitative insulin sensitivity check index (+0.009 +/- 0.01vs -0.006 +/- 0.01, p = 0.01). In addition, CoQ10 supplementation significantly decreased plasma malondialdehyde (MDA) (-0.6 +/- 0.5vs +0.5 +/- 1.0 mu mol/L, p < 0.001) and advanced glycation end products levels (AGEs) (-316.4 +/- 380.9vs +318.6 +/- 732.0 AU, p < 0.001) compared with the placebo. Supplementation with CoQ10had no significant impacts on fasting plasma glucose (FPG), lipid profiles, and matrix metalloproteinase-2 (MMP-2) compared with the placebo.Conclusions: Taken together, our study demonstrated that CoQ10 supplementation for 12weeks among DN patients had favorable effects on glucose metabolism, MDA, and AGEs levels, but unchanged FPG, lipid profiles, and MMP-2 concentrations.